| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1365-2516.2007.01567.X |
| P698 | PubMed publication ID | 18005150 |
| P2093 | author name string | Kimmelman J | |
| P2860 | cites work | Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 |
| Recent developments in gene transfer: risk and ethics | Q33709989 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| Paediatric care of the child with haemophilia | Q34636870 | ||
| Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer | Q34985105 | ||
| Gene therapy ethics and haemophilia: an inevitable therapeutic future? | Q35076713 | ||
| Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? | Q35666740 | ||
| Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A | Q36097677 | ||
| Gene therapy for hemophilia: an imperative to succeed | Q36157199 | ||
| Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients? | Q36230845 | ||
| Ethical issues in haemophilia. | Q36473033 | ||
| Cellular and genetic therapies for haemophilia | Q36473038 | ||
| Reasonable risks in clinical research: a critique and a proposal for the Integrative Approach | Q36524106 | ||
| Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion | Q38520320 | ||
| Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins | Q40446327 | ||
| Efficient lentiviral transduction of liver requires cell cycling in vivo | Q40909303 | ||
| Harm, ethics committees and the gene therapy death | Q43077649 | ||
| Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial | Q44328165 | ||
| Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. | Q44367374 | ||
| Direct exposure of mouse spermatozoa to very high concentrations of a serotype-2 adeno-associated virus gene therapy vector fails to lead to germ cell transduction | Q45666211 | ||
| Should gene therapy be used for newborns with hemophilia? | Q45858505 | ||
| Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer | Q45866661 | ||
| Direct exposure of mouse spermatogenic cells to high doses of adenovirus gene therapy vector does not result in germ cell transduction | Q45870367 | ||
| Clinical gene transfer studies for hemophilia B. | Q45875059 | ||
| Gene therapy for hemophilia? Yes. | Q45877159 | ||
| Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. | Q45877779 | ||
| Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors | Q45879602 | ||
| Gene therapy for hemophilia? | Q45884115 | ||
| Ethics of haemophilia care in the developing world | Q45885976 | ||
| When are research risks reasonable in relation to anticipated benefits? | Q49287946 | ||
| Phase I cancer trials. A collusion of misunderstanding. | Q52889998 | ||
| P433 | issue | 1 | |
| P921 | main subject | hemophilia | Q134003 |
| research ethics | Q1132684 | ||
| P304 | page(s) | 5-14 | |
| P577 | publication date | 2007-11-13 | |
| P1433 | published in | Haemophilia | Q15753375 |
| P1476 | title | Staunch protections: the ethics of haemophilia gene transfer research | |
| P478 | volume | 14 |
Search more.